ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.

Coronary Disease/mortality/therapy; Coronary Restenosis/prevention & control; Coronary Thrombosis/etiology/mortality; Drug-Eluting Stents/adverse effects/economics/standards; Epidemiologic Methods; France; Humans; Myocardial Infarction/mortality; Myocardial Revascularization/adverse effects/standards

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Daemen, Joost

Simoons, Maarten L.

Wijns, William

Bagust, Adrian

Bos, Gert

Bowen, James M.

Braunwald, Eugene

Camenzind, Edoardo

Chevalier, Bernard

Dimario, Carlo

More authors (78 more)

Language :

English

Title :

ESC Forum on Drug Eluting Stents European Heart House, Nice, 27-28 September 2007.

Publication date :

2009

Journal title :

European Heart Journal

ISSN :

0195-668X

eISSN :

1522-9645

Publisher :

Oxford University Press, United Kingdom

Volume :

Issue :

Pages :

152-61

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 31 May 2014

Statistics

Number of views

75 (1 by ULiège)

Number of downloads

132 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J 2005;26:804-847.
Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnar F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780.
Grube E, Silber S, Hauptmann KE, Mueller R, Buellesfeld L, Gerckens U, Russell ME. TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions. Circulation 2003;107:38-42.
Daemen J, Serruys PW. Drug-eluting stent update 2007: part I. A survey of current and future generation drug-eluting stents: meaningful advances or more of the same? Circulation 2007;116:316-328.
McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, Suddath WO, Weissman NJ, Torguson R, Kent KM, Pichard AD, Satler LF, Waksman R, Serruys PW. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004;364:1519-1521.
Camenzind E, Steg PG, Wijns W. Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation 2007;115:1440-1455; discussion 1455.
Morice MC, Serruys PW, Barragan P, Bode C, Van Es GA, Stoll HP, Snead D, Mauri L, Cutlip DE, Sousa E. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial. J Am Coll Cardiol 2007;50:1299-1304.
Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006;27:2784-2814.
Lagerqvist B, James SK, Stenestrand U, Lindback J, Nilsson T, Wallentin L. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007;356:1009-1019.
Pfisterer M, Brunner-La Rocca HP, Buser PT, Rickenbacher P, Hunziker P, Mueller C, Jeger R, Bader F, Osswald S, Kaiser C. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48:2584-2591.
Schampaert E, Cohen EA, Schluter M, Reeves F, Traboulsi M, Title LM, Kuntz RE, Popma JJ. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004;43:1110-1115.
Stone GW, Ellis SG, Cox DA, Hermiller J, O'shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004;350:221-231.
Holmes DR Jr., Leon MB, Moses JW, Popma JJ, Cutlip D, Fitzgerald PJ, Brown C, Fischell T, Wong SC, Midei M, Snead D, Kuntz RE. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation 2004;109:634-640.
Colombo A, Drzewiecki J, Banning A, Grube E, Hauptmann K, Silber S, Dudek D, Fort S, Schiele F, Zmudka K, Guagliumi G, Russell ME. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108:788-794.
Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:989-997.
Kastrati A, Mehilli J, Pache J, Kaiser C, Valgimigli M, Kelbaek H, Menichelli M, Sabate M, Suttorp MJ, Baumgart D, Seyfarth M, Pfisterer ME, Schomig A. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007;356:1030-1039.
Stone GW, Moses JW, Ellis SG, Schofer J, Dawkins KD, Morice MC, Colombo A, Schampaert E, Grube E, Kirtane AJ, Cutlip DE, Fahy M, Pocock SJ, Mehran R, Leon MB. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.
Stettler C, Wandel S, Allemann S, Kastrati A, Morice MC, Schomig A, Pfisterer ME, Stone GW, Leon MB, de Lezo JS, Goy JJ, Park SJ, Sabate M, Suttorp MJ, Kelbaek H, Spaulding C, Menichelli M, Vermeersch P, Dirksen MT, Cervinka P, Petronio AS, Nordmann AJ, Diem P, Meier B, Zwahlen M, Reichenbach S, Trelle S, Windecker S, Juni P. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-948.
James S. Long Term Mortality after Drug-Eluting Stents in Sweden - One Additional Year of Follow-up. Vienna, Austia: European Society of Cardiology; 2007.
Jensen LO, Maeng M, Kaltoft A, Thayssen P, Hansen HH, Bottcher M, Lassen JF, Krussel LR, Rasmussen K, Hansen KN, Pedersen L, Johnsen SP, Soerensen HT, Thuesen L. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol 2007;50:463-470.
Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med 2007;357:1393-1402.
Mauri L, Silverstein T, Lovett A, Resnic FS, Normand S. long term clinical outcomes following drug-eluting and bare metal stenting in Massachusetts. Orlando, FL: American Heart Association Scientific Sessions; 2007.
Daemen J, Van Domburg R, Boersma E, de Jaegere P, Serruys P. A long-term survival analysis of 3 sequential cohorts of consecutive all comers (n = 6129) treated with bare-metal, sirolimus- or paclitaxel-eluting stents. Eur Heart J 2007;28(Suppl.):325.
Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, Popma JJ, Fitzgerald PJ, Kuntz RE. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol 2007;100(8B):45M-55M.
Serruys PW, Daemen J. Are drug-eluting stents associated with a higher rate of late thrombosis than bare metal stents? Late stent thrombosis: a nuisance in both bare metal and drug-eluting stents. Circulation 2007;115:1433-1439; discussion 1439.
Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, Kutys R, Skorija K, Gold HK, Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48:193-202.
Nebeker JR, Virmani R, Bennett CL, Hoffman JM, Samore MH, Alvarez J, Davidson CJ, McKoy JM, Raisch DW, Whisenant BK, Yarnold PR, Belknap SM, West DP, Gage JE, Morse RE, Gligoric G, Davidson L, Feldman MD. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol 2006;47:175-181.
Virmani R. Safety of Polymer Coating on Drug-Eluting Stents: What You Don't Know Could Kill You. Washington DC, MA: Transcather Cardiovascular Therapeutics (TCT); 2006.
Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, Stankovic G, Airoldi F, Chieffo A, Montorfano M, Carlino M, Michev I, Corvaja N, Briguori C, Gerckens U, Grube E, Colombo A. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. J Am Med Assoc 2005;293:2126-2130.
Daemen J, Kukreja N, van Twisk PH, Onuma Y, de Jaegere P, van Domburg R, Serruys PW. Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology hospital registry. Am J Cardiol 2007;101:1105-1111.
Daemen J, Wenaweser P, Tsuchida K, Abrecht L, Vaina S, Morger C, Kukreja N, Juni P, Sianos G, Hellige G, van Domburg RT, Hess OM, Boersma E, Meier B, Windecker S, Serruys PW. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369:667-678.
Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, Van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical endpoints in coronary stent trials - a case for standardized definitions. Circulation 2007;115:2344-2351
Fajadet J, Wijns W, Laarman GJ, Kuck KH, Ormiston J, Munzel T, Popma JJ, Fitzgerald PJ, Bonan R, Kuntz RE. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114:798-806.
Steg PG. Increased all-cause mortality at 2 year follow-up after PCI with drug-eluting stents vs bare metal stents in acute coronary syndromes: the GRACE registry experience. Vienna, Austria: European Society of Cardiology; 2007.
Kastrati A, Dibra A, Spaulding C, Laarman GJ, Menichelli M, Valgimigli M, Di Lorenzo E, Kaiser C, Tierala I, Mehilli J, Seyfarth M, Varenne O, Dirksen MT, Percoco G, Varricchio A, Pittl U, Syvanne M, Suttorp MJ, Violini R, Schomig A. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute myocardial infarction. Eur Heart J 2007;22:2706-2713.
Serruys P, Daemen J, Morice MC, de Bruyne B, Colombo A, Macaya C, Richardt G, Fajadet J, Hamm C, Dawkins K, Vranckx P, Bressers M, Van Domburg R, Schuijer M, Wittebols K, Pieters M, Stoll HP. Three-year follow-up of the ARTS-II* - Sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. Euro Intervention 2008;3:450-458.
Rodriguez AE, Maree AO, Mieres J, Berrocal D, Grinfeld L, Fernandez-Pereira C, Curotto V, Rodriguez-Granillo A, O'Neill W, Palacios IF. Late loss of early benefit from drug-eluting stents when compared with bare-metal stents and coronary artery bypass surgery: 3 years follow-up of the ERACI III registry. Eur Heart J 2007;28:2118-2125.
Brunner-La Rocca HP, Kaiser C, Bernheim A, Zellweger MJ, Jeger R, Buser PT, Osswald S, Pfisterer M, for the BASKET Investigators. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-months analysis. Lancet 2007;370:1552-1559.
Bowen J, Hopkins R, Chiu M, Blackhouse G, Lazzam C, Ko D, Tu JV, Cohen E, Campbell K, He Y, Willan A, Tarride JE, Goeree R. Clinical and cost-effectiveness analysis of drug eluting stents compared to bare metal stents for percutaneous coronary interventions in Ontario: final report [Report No. HTA002-0705-02]. Hamilton, ON: Program for Assessment of Technology in Health, St. Joseph's Healthcare Hamilton/McMaster University; 2007. http://www.path-hta. ca/report.htm. Available: http://wwwpath-htaca/reporthtm 2007.
Ong AT, Daemen J, van Hout BA, Lemos PA, Bosch JL, van Domburg RT, Serruys PW. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry. Eur Heart J 2006;27:2996-3003.
Silber S, Borggrefe M, Böhm M, Hoffmeister HM, Dietz R, Ertl G, Heush G. Positionspapier der DGK zur Wirksamkeit und Sicherheit van Medikamente freisentzenden Koronarstents (DES). Der Kardiol 2007;1:84-111.
Ormiston JA, Serruys PW, Regar E, Thuesen L, Webster MWI, Onuma Y, Garcia-Garcia HM, McGreevy R, Veldhof S. A bioabsorbable everolimus-eluting coronary stent system for patients with singel de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899-907.
Erbel R, Di Mario C, Bartunek J, Bonnier J, de Bruyne B, Eberli FR, Erne P, Haude M, Heublein B, Horrigan M, Ilsley C, Böse D, Koolen J, Lüscher TF, Weissman N, Waksman R for the PROGRESS-AMS (Clinical Performance and Angiography Results of Coronary Stenting with Absorbable Metal Stents) Investigators. Lancet 2007;369:1869-1975.
Serebruany VL, Steinhubl SR, Berger PB, Malinin AI, Bhatt DL, Topol EJ. Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005;45:246-251.
Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015